PABPN1 gene therapy for oculopharyngeal muscular dystrophy

PABPN1 gene therapy for oculopharyngeal muscular dystrophy

Oculopharyngeal muscular dystrophy is caused by trinucleotide repeat expansions in thePABPN1gene. Here the authors use AAV-based gene therapy to knockdown the mutant gene and replace it with a wild-type allele, and show effectiveness in mice and in patient cells.

Detalles Bibliográficos
Autores principales: A. Malerba, P. Klein, H. Bachtarzi, S. A. Jarmin, G. Cordova, A. Ferry, V. Strings, M. Polay Espinoza, K. Mamchaoui, S. C. Blumen, J. Lacau St Guily, V. Mouly, M. Graham, G. Butler-Browne, D. A. Suhy, C. Trollet, G. Dickson
Formato: Artículo
Lenguaje:English
Publicado: Nature Portfolio 2017-03-01
Colección:Nature Communications
Acceso en línea:https://doi.org/10.1038/ncomms14848

Internet

https://doi.org/10.1038/ncomms14848

Ejemplares similares